1[1]Alberti KGMM, Zimmet PZ.For the WHO Consultation:definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation.Diabetes Med,1998, 15: 539～553
同被引文献6
1[1]Cambell RK.Glimepiride:Role of new sulfonylurea in the treatment of type 2 diabetes mellitus.Ann Pharmacother,1998,32:1 044.
2[2]Haffner SM,Gonzalez C,Mietnen H,et al.A prospective analysis of the HOMA model.The Mexico City Diabetes Study.Diabtes Care,1997,20:1 138-1 141.
3[3]Korytkowski M,Thoms A,Reid L,et al.Glimepiride improves both first and second phase of insulin secretion in type 2 diabetes.Diabetes Care,2002,25(9):1 607-1 611.
4[4]Rosak C.The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents.J Diabetes Complication,2002,16(1):123-132.
5[7]Muller G,Hartz D,Punter J,et al.Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor.I.Binding Characteristics.Biochim Biophys Acta,1994,1191:267.
